Bismuth-213 and Actinium-225 - Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Bismuth-213 and Actinium-225 - Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
复制标题
DOI：
10.2174/1874471011205030221
复制
发表时间：
2012-01-01
影响因子：
2.3
通讯作者：
Apostolidis, Christos
中科院分区：
文献类型：
--
作者：
Morgenstern, Alfred;Bruchertseifer, Frank;Apostolidis, Christos
α发射体Ac-225和Bi-213是有前景的治疗性放射性核素，可用于癌症和感染性疾病的靶向α治疗。两种α发射器均可从已建立的放射性核素发生器获得高比活度。它们良好的化学和物理特性导致了大量临床前研究和几项临床试验的进行，证明了Ac-225和Bi-213靶向α治疗的可行性、安全性和治疗效果。本文介绍了Ac-225和Bi-213的生产方法，并概述了Ac-225/Bi-213放射性核素产生系统。重点介绍了选定的临床前研究，并总结了目前Ac-225和Bi-213的临床经验。
The alpha emitters Ac-225 and Bi-213 are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with Ac-225 and Bi-213. This review describes methods for the production of Ac-225 and Bi-213 and gives an overview of Ac-225/Bi-213 radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with Ac-225 and Bi-213 is summarized.